Amarin to Present at the Jefferies 2011 Global Healthcare Conference

MYSTIC, Conn. and DUBLIN, Ireland, June 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, will present at the Jefferies 2011 Global Healthcare Conference to be held at the Grand Hyatt in New York City. The presentation will take place on June 6, 2011 at 2:30 p.m. local time. A live Webcast of the presentation will be available at the following URL:

http://www.wsw.com/webcast/jeff60/amrn/

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). The Company reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>500 mg/dL]), as reported on November 29, 2010 and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [>200 and <500mg/dL] with mixed dyslipidemia), as reported on April 18, 2011. Both the MARINE and the ANCHOR trials were conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.

CONTACT: Investor Contact Information:

         Stephen D. Schultz

         Investor Relations and Corporate Communications

         Amarin Corporation

         In U.S.: +1 (860) 572-4979 x292

         investor.relations@amarincorp.com



         Lee M. Stern

         The Trout Group

         In U.S.: +1 (646) 378-2922

         lstern@troutgroup.com



         Media Contact Information:

         David Schull or Martina Schwarzkopf, Ph.D.

         Russo Partners

         In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)

         +1 (347) 591-8785 (mobile)

         david.schull@russopartnersllc.com

         martina.schwarzkopf@russopartnersllc.com

News Provided by Acquire Media

Close window | Back to top

• delicious
• Digg
• Facebook
• LinkedIn
• Twitter
• Yahoo! Buzz